» Articles » PMID: 37306932

Punicalagin Alleviates the Hyperproliferation of Keratinocytes in Psoriasis Through Inhibiting SKP2 Expression

Overview
Journal J Nat Med
Publisher Springer
Date 2023 Jun 12
PMID 37306932
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriasis is a chronic inflammatory skin disorder characterized by abnormal keratinocytes proliferation and multiple immune cells infiltration in the dermis and epidermis. Although most psoriasis-related researches have been concentrated on the interleukin-23 (IL-23)/interleukin-17 (IL-17) axis, new data suggest that keratinocytes also play a pivotal role in psoriasis. Previously, we found that punicalagin (PUN), a bioactive ellagitannin extracted from Pericarpium Granati (the pericarpium of Punica granatum L.), exerts a therapeutic effect on psoriasis. However, the underlying mechanism, especially its potential modulatory effect on keratinocytes, remains obscure. Our study aims to reveal the potential regulatory effect and its underlying cellular mechanism of PUN on the hyperproliferation of keratinocytes. We used tumor necrosis factor α (TNF-α), IL-17A and interleukin-6 (IL-6) to induce abnormal proliferation of HaCaT cells (Human Keratinocytes Cells) in vitro. Then, we evaluated the effects of PUN through MTT assay, EdU staining and cell cycle detection. Finally, we explored the underlying cellular mechanisms of PUN via RNA-sequencing, WB in vitro and in vivo. Here, we found that PUN can directly and dose-dependently decrease TNF-α, IL-17A and IL-6-induced abnormal proliferation of HaCaT cells in vitro. Mechanically, PUN suppresses the hyperproliferation of keratinocytes through repressing S-phase kinase-associated protein 2 (SKP2) expression in vitro and in vivo. Moreover, overexpression of SKP2 can partly abolish PUN-mediated inhibition of aberrantly proliferative keratinocytes. These results illustrate that PUN can reduce the severity of psoriasis through directly repressing SKP2-mediated abnormal proliferation of keratinocytes, which gives new insight into the therapeutic mechanism of PUN on psoriasis. Moreover, these findings imply that PUN might be a promising drug candidate for the treatment of psoriasis.

Citing Articles

Upregulated SKP2 Empowers Epidermal Proliferation Through Downregulation of P27 Kip1.

Tang L, Zhang B, Li G, Qiu X, Dai Z, Liu H Ann Dermatol. 2024; 36(5):282-291.

PMID: 39343755 PMC: 11439983. DOI: 10.5021/ad.23.118.


Natural Product-Derived Compounds Targeting Keratinocytes and Molecular Pathways in Psoriasis Therapeutics.

Lee Y, Jung Y, Choi H, Lee J, Lim T, Lee J Int J Mol Sci. 2024; 25(11).

PMID: 38892253 PMC: 11172960. DOI: 10.3390/ijms25116068.


Gentiopicrin-Loaded Chitosan Nanoparticles as a Topical Agent for the Treatment of Psoriasis.

Cheng G, Zhang X, Zhang H, Feng Z, Cai J, Li J Nanomaterials (Basel). 2024; 14(7).

PMID: 38607144 PMC: 11013271. DOI: 10.3390/nano14070610.

References
1.
Greb J, Goldminz A, Elder J, Lebwohl M, Gladman D, Wu J . Psoriasis. Nat Rev Dis Primers. 2016; 2:16082. DOI: 10.1038/nrdp.2016.82. View

2.
Wang S, Jiang Y, Miao H, Fang Y, Jiang N, Yu Y . Targeting rare tumors: new focus for clinical research in China. EMBO Mol Med. 2022; 15(1):e16415. PMC: 9832829. DOI: 10.15252/emmm.202216415. View

3.
Ding Y, Cui Y, Hou Y, Nie H . Bone marrow mesenchymal stem cell-conditioned medium facilitates fluid resolution via miR-214-activating epithelial sodium channels. MedComm (2020). 2021; 1(3):376-385. PMC: 8491198. DOI: 10.1002/mco2.40. View

4.
Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang Y, Homey B . Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007; 449(7162):564-9. DOI: 10.1038/nature06116. View

5.
Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles K, Tian S, Cardinale I . Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2010; 131(3):677-87. DOI: 10.1038/jid.2010.340. View